Last reviewed · How we verify
Nevirapine, zidovudine, lamivudine
Nevirapine, zidovudine, lamivudine is a Antiretroviral combination therapy (NNRTI + NRTIs) Small molecule drug developed by Institut de Recherche pour le Developpement. It is currently in Phase 3 development for HIV-1 infection.
This combination of three antiretroviral drugs inhibits HIV reverse transcriptase and non-nucleoside reverse transcriptase to suppress viral replication.
This combination of three antiretroviral drugs inhibits HIV reverse transcriptase and non-nucleoside reverse transcriptase to suppress viral replication. Used for HIV-1 infection.
At a glance
| Generic name | Nevirapine, zidovudine, lamivudine |
|---|---|
| Sponsor | Institut de Recherche pour le Developpement |
| Drug class | Antiretroviral combination therapy (NNRTI + NRTIs) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs). Together, they target different sites on the HIV reverse transcriptase enzyme, preventing the virus from converting its RNA genome into DNA and integrating into host cells. This triple-drug combination is designed to reduce viral load and slow disease progression in HIV-infected patients.
Approved indications
- HIV-1 infection
Common side effects
- Rash
- Hepatotoxicity
- Nausea
- Headache
- Anemia
- Peripheral neuropathy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding (PHASE2)
- A Prospective Cohort of Children With HIV Infection
- ARVs to Prevent Breastmilk HIV:Viral and Immune Responses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nevirapine, zidovudine, lamivudine CI brief — competitive landscape report
- Nevirapine, zidovudine, lamivudine updates RSS · CI watch RSS
- Institut de Recherche pour le Developpement portfolio CI
Frequently asked questions about Nevirapine, zidovudine, lamivudine
What is Nevirapine, zidovudine, lamivudine?
How does Nevirapine, zidovudine, lamivudine work?
What is Nevirapine, zidovudine, lamivudine used for?
Who makes Nevirapine, zidovudine, lamivudine?
What drug class is Nevirapine, zidovudine, lamivudine in?
What development phase is Nevirapine, zidovudine, lamivudine in?
What are the side effects of Nevirapine, zidovudine, lamivudine?
What does Nevirapine, zidovudine, lamivudine target?
Related
- Drug class: All Antiretroviral combination therapy (NNRTI + NRTIs) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Institut de Recherche pour le Developpement — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Compare: Nevirapine, zidovudine, lamivudine vs similar drugs
- Pricing: Nevirapine, zidovudine, lamivudine cost, discount & access